In recent years, attempts to xenogenize tumour cells have been pursued in a number of laboratories. It has been achieved by several procedures, including exposure to nonpathogenic viruses (Lindenman et al., 1963; Kobayashi et al., 1970) , antitumour drugs (Bonmassar et al., 1970; Nicolin et al., 1972) , through chemical haptenization (Martin et al., 1971) or treatment with mutagens (Boon & Kellerman, 1977) .
The antitumour agent, (5-(3,3' dimethyl-l-triazeno)-imidazole-4-carboxamide (DTIC), employed in our experiments, has been found to be particularly effective in increasing the immunogenicity of certain experimental lymphomas (Bonmassar et al., 1972; Nicolin et al., 1976a) .
The new antigenic specificities, not detectable on parental cells are retained as a genetic character after cessation of DTIC treatment (Nicolin et al., 1974a) and induce an immune response in syngeneic hosts as evaluated by classical rejection experiments (Nicolin et al., 1976b; Riccardi et al., 1978) and by transfer of immune lymphocytes (Nicolin et al., 1974b; Nicolin et al., 1980; Romani et al., 1983) .
Furthermore, it has been shown that DTIC-altered tumour cells can elicit host resistance to a subsequent inoculum of untreated tumour cells (Campanile et al., 1975; Nicolin et al., 1981) . In this respect DTIC treatment of tumour cells is likely to have some significance for immunotherapeutic approaches against neoplastic cells.
However, many fundamental questions related to the mechanism of immunological alterations and to the molecular characteristics and the functions, if any, of the DTICinduced antigens remain unanswered.
The aim of this study was to further investigate antigenic changes detected in the tumour cell surfaces after DTIC treatment. We wished to know whether DTIC induces new antigen(s) (Bonmassar et al., 1979) rather than amplifying a pre-existent tumour-associated antigen (TAA) (Mihich, 1969; Fuji et al., 1979) or induces a product that behaves like a restriction element for the recognition of an antigen already expressed on untreated tumours (Hui et al., 1984) . Another purpose of this study was to determine the immunological relationship among genetically homogeneous L1210 cells, distinctly xenogenized through different cycles of DTIC treatments, using syngeneic cytolytic T-lymphocytes (CTL) and the derived clones.
Materials and methods

Animals
Hybrid (BALB/c H-2d xDBA/2 H-2 d)F1 (hereafter called CD2F1) mice of both sexes, 6-8 weeks old were obtained from Charles River Breeding Laboratories (Calco, Italy). Tumours L1210 Cr (H-2d) (Law et al., 1949; Dunham et al., 1953) obtained from the National Cancer Institute (Bethesda, USA) and maintained in the laboratory by weekly i.p. injection into CD2F1 mice was cloned in vitro by limiting dilution. Twenty cells from one clone (20 cells/4 ml) were injected (0.2 ml/mouse) into 20 syngeneic mice. Four of 8 subcloned tumour lines (referred to as A, D, R, S) were transformed in vivo with DTIC, as previously described (Bonmassar et al., 1970) . Briefly, 106 tumour cells were injected i.p. into CD2F1 mice treated for 7 consecutive days with DTIC (100mg kg -1day-1, i.p.) starting one day after tumour challenge. When the ascitic tumours developed in the DTIC-treated mice, they were collected and 106 cells were transplanted into untreated mice. The same procedure was followed for 4-5 transplant generations. DTIC were maintained in compatible, total body Xiiradiated (3.5Gy; Securix Compact CGD), mice. -YAC-1(H -2a) tissue culture cell line originating from YAC (Klein & Klein, 1964) (Varnier & Levy, 1979; Rowe et al., 1970 Table I show that xenogenized DTIC subclones retained the growth characteristics of the untreated L1210 parental subclones, since their tumorigenicity in immunosuppressed mice was fully retained. The antigenic properties of the L1210/DTIC subclones and their reciprocal immunological relationships were studied with CTL. Spleen cells from CD2F1 mice that had rejected 107 xenogenized cells were secondarily restimulated in vitro with the relevant DTIC subclones. The results for the immunological cross-reactivities among L1210 DTIC subclones are listed in Table II .
In the 4h 51Cr-release assay, anti-D/DTIC CTL had high lytic activity against D/DTIC target cells as well as against the other DTIC subclone lines. The parental, DTICuntreated D subclone line was also lysed by anti-D/DTIC CTL, although the percentage of 51Cr release was lower than that released by D/DTIC. The other untreated cell lines (A,R,S) were recognized and lysed to a lesser degree than D. There was detectable activity against YAC and P388 lymphomas. Similar patterns of cross-reactivity were displayed by anti-A/DTIC, anti-R/DTIC and anti-S/DTIC CTL (data not shown). Indeed the CTL to each xenogenized subclone were fully cross-reactive with the other DTIC treated subclones.
To further understand the antigenic properties of DTIC subclones, D/DTIC CTL were cloned in microtiter plates by limiting dilution and cultured in the presence of irradiated D/DTIC cells, syngeneic feeder spleen cells and rat IL-2. Three weeks later, it was possible to detect growing colonies in 94/288 microwells. Since the percentage of negative wells was -67%, a high probability of cloning was ensured. The cytotoxic activity (lytic activity) of individual clones was assayed against the xenogenized cells, the untreated parental subclones and unrelated tumours. Twenty-one of the 94 CTL clones obtained had no lytic activity and 73 had cytotoxic activity. Among the 73 effective CTL clones, 36 had high cytotoxic activity against the 4 xenogenized subclone cells only (Table III) , in contrast to the 12 CTL clones that had lytic activity against the L1210 subclone cells also (Table  IV) , whether xenogenized or not. None of the CTL clone groups had any effect on the unrelated tumour cells. Two CTL clones were weakly but highly specifically lytic to the cD/T=dead mice/treated mice; d3.5 Gy/mouse (day-1). (Henney et al., 1981; Suzuki et al., 1983) and/or LAK cells (Rosenstein et al., 1984; Merluzzi, 1984 (Silvestrini et al., 1977) . The modification at the molecular level is still unknown. Studies of DTIC-induced antigenicity and of similar immunological alterations produced in different tumour cells by other anticancer compounds (Mihich, 1969; Nicolin et al., 1972; Frost, 1984) , or mutagenic agents (Boon, 1983; Altevog et al., 1985) , have been hampered by difficulties in raising effective polyclonal or monoclonal antibodies. Further characterization of DTIC antigens might be useful in shortening the time schedule required to xenogenize the tumour cells, in order to achieve the tumour rejection in primary hosts. Furthermore the DTIC-induced antigens might be exploited for active vaccination or passive immunotherapy.
Previous studies with cell-mediated cytotoxic assays from this laboratory (Marelli et al., 1986) Zac-Nejmark et al., 1978) .
Two CTL clones showed weak but highly specific reactivity against the immunizing target (D/DTIC) cells and the respective untreated lines (D). Although the parental cell lines D, A, R, S were derived from one clone of L1210, a mutational event occurred before the DTIC treatment could be responsible for the induction of a determinant on the untreated D cell line that is retained on D/DTIC cells. The antigens recognized by the 23 clones that behave in a nonspecific way could belong to the category of molecules that are targets for LAK or activated NK.
We did exclude that they are classical NK targets, since L1210 cells (Fuji & Iribe, 1986) were not NK sensitive. Moreover the parental and DTIC treated subclones involved in this study were not lysed in classical NK experiments (data not shown).
Little is known so far about the mechanism by which alkylating compounds, such as DTIC (Audette et al., 1973) , have such a strong effect on the immunogenicity of tumour cells. Since DTIC treatment has to be protracted to obtain tumour lines rejected by a syngeneic host, it is quite likely that more than one mutational event occurs, but probably only a few of these lead to increased antigenicity. Furthermore, our results suggest that DTIC induces mutations, leading to the recurrent expression of new antigens at preferential sites.
Studies are in progress to elucidate the biochemistry and genetics of DTIC induced-antigens.
Whatever the chemical structure of the DTIC-induced antigens, the data presented in this paper may prove useful for a chemo-immunological approach to tumour therapy. 
